Wilms' tumor (WT) is the most common childhood renal cancer. Although mutations in known tumorassociated genes (WT1, WTX , and CATNB) occur only in a third of tumors, many tumors show evidence of activated -catenin-dependent Wnt signaling, but the molecular mechanism by which this occurs is unknown. A key obstacle to understanding the pathogenesis of WT is the paucity of mouse models that recapitulate its features in humans. Herein, we describe a transgenic mouse model of primitive renal epithelial neoplasms that have high penetrance and mimic the epithelial component of human WT. Introduction of a stabilizing -catenin mutation restricted to the kidney is sufficient to induce primitive renal epithelial tumors; however, when compounded with activation of K-RAS, the mice develop large, bilateral, Wilms' tumor (WT) is an embryonal tumor of the kidney that is the most common childhood renal cancer and the fourth most common childhood malignancy overall.
1,2Modern multimodal management can cure 95% of patients with WT with the most favorable risk profile 3-7 but at the cost of significant short-and long-term morbidity.
-11In addition, there remains a persistent cohort of children who ultimately fail therapy and die.3 Consequently, the main research priorities for WT are to lower the toxicity while maintaining efficacy of existing therapy for lowerrisk patients and to develop novel therapeutics for higherrisk patients. Achieving these goals depends on understanding the mechanisms underlying WT oncogenesis and progression.WTs are triphasic, embryonic tumors that classically have varying amounts of blastemal elements, primitive mesenchymal stroma, and primitive epithelia. They are generally thought to arise from nephrogenic rests (ie, embryonic tissue) derived from the metanephric mesenchyme during renal development. The genetic aberrations underlying this process are known to be heterogeneous 12 and can include inactivating mutations of Wilms' tumor 1 gene (WT1), 13,14 Wilms' tumor gene found on chromosome X (WTX), [15][16][17] and stabilizing/activating mutations of -catenin (CTNNB1). 18,19 The precise mechaSupported in part by NIH grants K08 CA113452 (P.E.C.), DK065123 (R.Z.), DK075594 (R.Z.), DK65123 (R.Z.), and P30 DK079341 (P.E.C. and R.Z.); an American Heart Association Established Investigator Award (R.Z.); and a Merit Award from the Department of Veterans Affairs (R.Z.).Accepted for publication August 10, 2011. CME Disclosure: None of the authors disclosed any relevant financial relationships.Address reprint requests to Peter E. Clark, M.D., Associate Professor Urologic Surgery, Vanderbilt University Medical Center, A-1302 Medical Center North, Nashville, TN 37232-2765. E-mail: peter.clark@ vanderbilt.edu.